The Nagoya Protocol is an international agreement under the Convention on Biological Diversity (CBD) that governs access to genetic resources and ensures fair and equitable sharing of benefits arising from their use.

The Nagoya Protocol directly impacts businesses using genetic resources by imposing legal obligations on access, use, and benefit-sharing. Non-compliance can result in fines, loss of IP rights, and restricted market access.

Pharmaceuticals, Biotechnology, Agriculture, Cosmetics, Nutraceuticals, and any sector relying on ingredients from genetic resources.

R&D on biological materials, product development using natural ingredients, commercialization of bio-based products, and use of traditional knowledge.

Businesses must obtain official approval from the provider country before accessing genetic resources, often involving government authorities and local communities.

Legally binding agreements defining how benefits (royalties, milestones, tech transfer) are shared between businesses to provider countries or community.

Businesses must ensure traceability of genetic resources, verify legal access, and integrate compliance checks into procurement and sourcing processes.

Financial penalties, litigation, invalidation of patents, product recalls, and reputational damage.